In this episode of Peptides Explained, John Garrett, RN, breaks down: What AOD-9604 is and how it differs from full-length HGH Lipolysis, lipogenesis, and beta-3 adrenergic signaling Why animal studies looked promising What the early human trials showed Why the obesity-development program was discontinued Whether AOD-9604 raises IGF-1 Regulatory status, risks, unknowns, and anti-doping concerns A responsible framework for evaluating experimental fat-loss peptides The central takeaway: AOD-9604 has a plausible preclinical mechanism, but the available human evidence does not establish dependable, clinically meaningful fat loss
Peluso G, Barbarisi A, Savica V, Reda E, Nicolai R, Benatti P, Calvani M: Carnitine: an osmolyte that plays a metabolic role
How is PlexusDx tirzepatide different in terms of side effects
Help detox and rejuvenate your body with Liposomal
With that regulatory brake reduced, IGF-1 LR3 interacts with IGF-1 receptors more directly and for a longer duration, which is why research protocols report a half-life of roughly 2030 hours, compared to native IGF-1s 1215 hours
Significantly reduced protein intake over an extended period may contribute to hair thinning for some people